New β-lactam antibiotics were obtained by coupling the cephalosporin Cefotaxime with monobactams in order to assess the possibility to enhance the cephalosporin activity through a synergistic dual-action mechanism. The activities were tested, in vitro, against a panel of selected bacteria. Preliminary results showed a light change in antibacterial activity when compared with that of the starting cephem counterpart.
Introduction
The dual-action mechanism exploited by cephalosporins coupled with other antibiotics has been described. 1 To the best of our knowledge, no dual action products arising from the coupling between two β-lactam moieties have been reported, so far. In the present paper we describe the synthesis and the antibacterial activity of new compounds deriving from the above reported chemical linkage. A cephem and a monobactam moiety, both acting against bacterial cell wall targets, were used as parent compounds.
The expected dual action of the cephem-monobactam molecule and the monobactam, when released after enzymatic displacement, was based on the possible synergism resulting from a simultaneous action of these two moieties against different penicillin binding proteins (PBPs). 10 The chosen β-lactam moieties have been Cefotaxime 11 (see Table 2 ), well known for its antibacterial activity, and monobactams 11, (E) The anti and the syn isomers of the methoxyiminopyridin-3-ylacetic acids (E)-10 and (Z)-10 were obtained by treating oxopyridin-3-ylacetic acid 14 (synthesized by oxidation of 3-acetylpyridine 13 as reported in the literature 16 ) with O-methylhydroxylamine (Scheme 3). After esterification with diazomethane the two isomers were separated by flash chromatography and were subsequently hydrolyzed to the free acids (E)-10 and (Z)-10: The configuration was assigned on the basis of the relative rates of methyl ester hydrolysis. In fact, for a series of α-alkoxyimino esters it has been demonstrated that the Z isomers (syn) hydrolyze much more slowly than the corresponding E forms (anti). (Table  2) , and compound (Z,Z)-2 was even somewhat more active than Cefotaxime against one strain of E. coli and one strain of K. pneumoniae. Since compounds (Z,E)-2, (Z,Z)-2 differ only in the geometry of the monobactam moiety's methoxy-imine, their chemophysical properties have to be very similar. Thus, if the activity of these compounds had to be ascribed only to the cephem nature without any concomitant dual action, it would be hard to understand the differences between the antibacterial activity of (Z,E)-2, (Z,Z)-2. Otherwise, stating the occurrence of the dual action mechanism, these differences can be ascribed to the release of an inactive monobactam moiety in the case of the compound (Z,E)-2 and of an active one in the case of the compound (Z,Z)-2. Since this dual-action mechanism should depend on the PBP's and/or β-lactamases, it could happen that it is exploited to a different extent in different bacterial species and strains. In contrast, compound (Z,Z)-3, derived from coupling of Cefotaxime with Aztreonam (Z)-7, was less active than either Cefotaxime or Aztreonam alone. This poor activity could be caused by a difficult cell wall penetration due to the total negative charge. Furthermore, the comparison of its activity with that of Aztreonam, that is better against Gram-positive organisms but worst against Gram-negative, may suggest that compound (Z,Z)-3 maintains a cephalosporin-type spectrum of activity without significantly releasing the monobactam counterpart, as a consequence of a possible preferred primary interaction between the monobactam-ring and its target PBPs in Gram negative bacteria. These results strongly suggest that the expected dual-action mechanism is at least partially exploited. Work is in progress in order to assess the possibility of exploiting a dual action mechanism by coupling different β-lactam-antibiotics. 
Experimental Section
General Procedures. All starting compounds, unless otherwise stated, were purchased. Reactions were run under an atmosphere of dry nitrogen or argon. FT-IR Spectra were recorded on a Perkin-Elmer infrared spectrometer, mass spectra at 70 eV, using the electron impact mode were obtained on Finnigan MAT GCQ instrument, NMR spectra on spectrometers Varian VXR 200, Varian Gemini 300, or Varian Mercury 400 MHz using the residual signal of the solvent as internal standard. HPLC analysis were carried out using a HP 1100 instrument, column Hibar Lichrospher 100 RP-18 (5µm), eluting with a gradient from KH 2 PO 4 buffer (0.01N, pH 3.2) to MeCN/ KH 2 PO 4 buffer 85/15.
(E) and (Z)-2-(Methoxyimino)-2-(3-pyrid-3-yl)acetic acid [(E)-10] and [(Z)-10]. O-Methyl-
hydroxylamine hydrochloride (8.3g, 98 mmol, 32.5 mL of a 25% solution in water) was added at room temperature and stirring to oxopyridin-3-ylacetic acid 14 (3.7g, 24 mmol). The pH 5 was adjusted by adding a saturated solution of NaHCO 3 . The resulting mixture was stirred over night affording a homogeneous solution (pH 5.2). 1N HCl was added to adjust pH 4, and the water was removed in vacuo to afford a white solid. This product was dissolved in methanol and heated to 60 °C under stirring. The precipitate was separated by decantation and was a mixture of (E)-10 and (Z)-10, which was trearted diazomethane. Separation of the corresponding methyl esters by flash chromatography (cyclohexane/ethyl acetate 7:3) followed by hydrolysis with NaOH/MeOH, and subsequent addition of HCl (aq) to adjust pH 4.2) afforded the acids (E)-10 (2.54 g, 58%) and (Z)-10 (0.52g, 12% 
A cooled (0 °C) solution of N-[(2S*,3S*)-2-methyl-4-oxo-1-(2-trityl-2H-tetrazol-5-yl)azetidin-3-
yl]carbamic acid tert-butyl ester 8 (227 mg, 0.45 mmol) in trifluoroacetic acid (99%, 3 mL) was allowed to warm to room temperature within 10 min under a stream of nitrogen. The trifluoroacetic acid was then removed in vacuo at room temperature affording a yellow oil. This product was dissolved under nitrogen in dry acetonitrile (15 mL), and, at 0 °C triethylamine (1.575 mL, 1. Following the same procedure and using the appropriate reagents products (5) and (E)-6 were obtained in the yields reported in square brackets. -4-oxo-1-(2-trityl-2H-1,2,3,4-tetrazol-5-yl) The same procedure employing azetidinones (E)-6 and (Z)-7 were used for the synthesis of coupling products 1 and 2. The relative yields are reported in square brackets.
N1-[(2R*,3R*)-2-Methyl

